Jennifer Fulton, MD
Pulmonary Disease · Jacksonville, FLNPI 1083783609
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $518,199 of the $664,625 with a category attached, or 78.0%. 55 manufacturers reported payments, led by Sanofi at 55.9% of the total. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,185 payments — averaging $560.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$372K
- Regeneron Healthcare Solutions, Inc.$183K
- Boehringer Ingelheim$49K
- AstraZeneca$21K
- Pfizer$20K
- E.r. Squibb & Sons, L.L.C.$5K
- plus $15K from 49 others
Across 56 payments — averaging $2262.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$107K
- Pfizer$19K
What the payments were for
- Consulting fees$40,4316%
- Speaking & faculty fees$518,19978%
- Travel & lodging$77,47712%
- Food & beverage$28,4604%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$580,318
- ELIQUIS$24,043
- BREZTRI$19,256
- Impella$2,827
- Indigo System$1,416
- STIOLTO RESPIMAT$950
- TYVASO$250
- CLEANER$147
- ORENITRAM$136
- REMODULIN$136
- FloTrac Sensor$135
- OFEV$122
- TEZSPIRE$114
- ENTRESTO$109
- Arikayce$108
How this compares
$664,625 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 138 | $104,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $81,182 |
| Spiriva RespimatTiotropium Bromide | 92 | $64,402 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $55,517 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $55,472 |
| Advair HfaFluticasone Propion/Salmeterol | 85 | $34,629 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $25,060 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $15,256 |
| DuleraMometasone/Formoterol | 29 | $10,281 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 23 | $8,719 |
| Advair DiskusFluticasone Propion/Salmeterol | 30 | $7,956 |
| Arnuity ElliptaFluticasone Furoate | 26 | $7,582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 263 | $5,779 |
| BreynaBudesonide/Formoterol Fumarate | 28 | $4,891 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,074 | $169,340271 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $21,131 | $128,372214 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $48,714 | $119,874180 claims |
| MerckDulera | $517 | $10,28129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
- Franck RahaghiWeston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.